Stockwinners Market Radar for June 17, 2018 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

Settings & Search

TWX...		Hot Stocks 16:58 EDT Box Office Battle: 'Incredibles 2' breaks record with $180M - Disney (DIS) and Pixar's "Incredibles 2" opened to a record-shattering $180M from 4,410 theaters over the weekend, scoring the biggest launch ever for an animated film and the eighth-biggest opening of all time, not adjusted for inflation. Overseas, the movie debuted to $51.5M from its first 25 markets for a global launch of $231.5M. "Incredibles 2" earned an A+ CinemaScore and sports a 94% Rotten Tomatoes score. BOX OFFICE RUNNERS-UP: Warner Bros. (TWX) and Village Roadshow "Ocean's 8" fell to number 2, grossing $19.6M for a 10-day domestic total of $79.2M. Behind it was New Line's male-led ensemble comedy "Tag," with $14.6M from 3,383 theaters in its debut. Disney's "Solo: A Star Wars Story" placed number 4, earning $9.1M. Rounding out the top five, Ryan Reynolds and Fox's (FOXA) "Deadpool 2" ended the weekend with an estimated $8.8M. Other publicly traded companies in filmmaking include Lionsgate (LGF.A), Viacom's (VIAB), Comcast's (CMCSA; CMCSK) and Sony (SNE).
F		Hot Stocks 16:25 EDT Ford acquires Michigan Central Station - Ford Motor has acquired the iconic Michigan Central Station and plans to transform it into the centerpiece of a new campus in Detroit's Corktown neighborhood that will serve as an innovation hub for Ford's vision for the future of transportation. The acquisition of Michigan Central Station comes alongside the company's purchase of the former Detroit Public Schools Book Depository, two acres of vacant land, the site of an old brass factory and the recent purchase of a refurbished former factory in Corktown, now home to Ford's electric vehicle and autonomous vehicle business teams. Initial plans include locating approximately 2,500 Ford employees, most from the mobility team, to call Corktown their work home by 2022. There will also be space to accommodate 2,500 additional employees of partners and other businesses among Michigan Central Station and the other developments.
BMY		Hot Stocks 16:22 EDT Bristol-Myers' ELOQUENT-3 trial meets primary endpoint - Bristol-Myers Squibb announced that the ELOQUENT-3 trial, an international Phase 2 study evaluating the addition of Empliciti to pomalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma, achieved its primary endpoint, showing a statistically significant and clinically meaningful improvement in progression-free survival for patients treated with EPd compared with pomalidomide and dexamethasone alone. ELOQUENT-3 is the only randomized, active-controlled trial to investigate a pomalidomide-based triplet combination in patients with RRMM who received at least two prior therapies, including lenalidomide and a proteasome inhibitor. Twice as many patients randomized to EPd responded to therapy compared to patients randomized to Pd alone. Patients randomized to EPd demonstrated an overall response rate of 53%, compared with 26% among patients randomized to Pd. Time to first response was comparable for patients receiving EPd and Pd at 1.95 and 1.91 months, respectively. Median duration of response had not been reached among patients randomized to EPd at time of analysis. Overall survival, a secondary endpoint, although not mature at this time, showed a positive trend favoring EPd over Pd alone. Treatment-related Grade 3-4 adverse events were comparable between EPd and Pd groups.
PTCT RHHBY		Hot Stocks 16:18 EDT PTC Therapeutics presents updated preliminary data from SMA FIREFISH Program - PTC Therapeutics (PTCT) announced the presentation of updated interim clinical data from Part 1 of the FIREFISH study investigating risdiplam in babies with Type 1 Spinal Muscular Atrophy, at the 22nd Annual SMA Researcher Meeting. The data presented demonstrated that at Day 182, over 90% of the babies achieved a greater than 4-point increase in CHOP-INTEND score compared to baseline. The CHOP-INTEND data were further supported by video footage presented by Dr Baranello demonstrating antigravity movements, the ability to control their head, roll, or sit in babies participating in FIREFISH. Part 2 of the pivotal FIREFISH study is ongoing. The SMA program is a collaboration between PTC, Roche (RHHBY), and the SMA Foundation. Other presentations included an analysis of data from Part 1 of the SUNFISH study which demonstrated that risdiplam administration resulted in a dose-dependent increase in SMN protein levels up to 3.5-fold; pharmacodynamic data from the JEWELFISH trial; and preclinical data demonstrating SMN protein production and distribution, as well as the development of the SMA Independence Scale.
CYTK		Hot Stocks 16:15 EDT Cytokinetics announces data from Phase 2 clinical study of Reldesemtiv in SMA - Cytokinetics announced data from the Phase 2 clinical study of reldesemtiv in patients with spinal muscular atrophy, or SMA, were presented at the 2018 Annual Cure SMA Conference in Dallas. This hypothesis-generating study met its primary objective to determine potential pharmacodynamic effects of reldesemtiv after multiple oral doses in patients with SMA, and secondary objectives to evaluate the safety, tolerability and pharmacokinetics of reldesemtiv. In collaboration with Astellas, Cytokinetics is developing reldesemtiv as a potential treatment for people with SMA and certain other debilitating diseases and conditions associated with skeletal muscle weakness and/or fatigue. The study showed dose- and concentration-dependent increases in time to muscle fatigue as measured by changes from baseline in Six Minute Walk Distance, a sub-maximal exercise test of aerobic capacity and endurance, and Maximal Expiratory Pressure, a measure of strength of respiratory muscles, after eight weeks of treatment with reldesemtiv. The study, which examined two dose levels of reldesemtiv, 150 mg or 450 mg twice daily, demonstrated dose-dependent increases in 6MWD in ambulatory patients as measured at both post-baseline time points, week four and week eight. The study also showed increases versus placebo in MEP. Adverse events were similar between groups receiving reldesemtiv and placebo. The most commonly observed adverse effects were headache, constipation and nausea. Four patients had serious adverse events reported that resulted in early termination of study drug treatment, all considered to be unrelated to reldesemtiv.
PERY		Hot Stocks 16:12 EDT Perry Ellis enters into $437M transaction to become private company - Perry Ellis International announced it has entered into a definitive merger agreement under which a newly formed entity controlled by George Feldenkreis, Perry Ellis' founder and member of the company's Board of Directors, will acquire all of the outstanding common shares of Perry Ellis not already beneficially owned by the Feldenkreis family for $27.50 per share in cash. Additionally, the company and George Feldenkreis have agreed to defer the next annual meeting for the election of directors while the merger agreement is pending. The purchase price represents a premium of approximately 21.6% to Perry Ellis' unaffected closing stock price on February 5, 2018, the last trading day prior to George Feldenkreis announcing his proposal to take the Company private. The transaction is valued at approximately $437M. The transaction was unanimously approved by the Perry Ellis Board of Directors, acting on the unanimous recommendation of a Special Committee of independent directors that was granted full authority to conduct a comprehensive strategic review and evaluate and, if warranted, negotiate the Feldenkreis acquisition proposal. Following completion of the transaction, Oscar Feldenkreis will continue to lead the company as Chief Executive Officer. George Feldenkreis, Director and Founder, will return to an active role in the management of the company. Perry Ellis will continue to be headquartered in Miami, Florida. Upon close, Perry Ellis will become a privately held company and Perry Ellis common shares will no longer be listed or traded on any public market. The transaction, which is expected to close in the second half of calendar year 2018, is subject to the satisfaction of customary closing conditions and approvals, including approval by Perry Ellis shareholders, receipt of regulatory approvals and other customary closing conditions.
VSTM		Hot Stocks 16:08 EDT Verastem presents duvelisib data at EHA 2018 annual meeting - Verastem announced one oral and three poster presentations at the 23rd Congress of the European Hematology Association being held June 14-17, 2018 in Stockholm, Sweden. Data were presented on the company's lead product candidate, duvelisib, a first-in-class oral dual inhibitor of phosphoinositide 3-kinase-delta and PI3K-gamma. An oral presentation by Matthew Davids, Dana-Farber Cancer Institute, highlighted the latest data from a Phase Ib/II study evaluating duvelisib in combination with FCR as a frontline treatment in younger patients with chronic lymphocytic leukemia. Three poster presentations highlighted additional duvelisib data, including crossover extension results from the Phase 3 DUO study in patients with relapsed or refractory CLL/small lymphocytic lymphoma, and new biomarker analyses on the tumor microenvironment modulation from the DUOTM study and the Phase 2 DYNAMOTM study in patients with refractory indolent non-Hodgkin lymphoma, and the dual PI3K-delta and PI3K-gamma activity of duvelisib in the CONTEMPOTM study in patients with untreated follicular lymphoma who are treated with duvelisib in combination with CD20 antibody immunotherapy. Phase Ib/II study of duvelisib in combination with FCR [dFCR] achieved ORR of 94% and 76% bone marrow MRD negativity in frontline therapy in younger CLL patients. Duvelisib also demonstrated robust clinical activity in CLL with 73% ORR and a median of 15-month PFS in the DUO crossover study of patients who became relapsed/refractory to ofatumumab in DUO. Additional data support the hypothesis that duvelisib, a first-in-class dual inhibitor of PI3K delta/gamma, targets malignant B-cells directly and modulates the tumor microenvironment.
IQ		Hot Stocks 16:05 EDT iQIYI obtains broadcasting rights for all four golf majors - iQIYI announced it had been awarded broadcasting rights for all four golf majors - professional golf's most important annual tournaments, making iQIYI the largest source for professional golf live streaming and video information in China. iQIYI was awarded online broadcasting rights for the prestigious U.S. Open golf tournament, having previously acquired the rights to stream golf's other three "Major Tournaments"-- Masters, The Open and PGA Championship.